Table 1.
Clinical Characteristics of IBD Patients and HC Subjects
| Biopsy Samples |
Blood Samples |
|||||
|---|---|---|---|---|---|---|
| HC Subjects | Patients With CD (A/R) | Patients With UC (A/R) | HC Subjects | Patients With CD (A/R) | Patients With UC (A/R) | |
| Number of patients | 44 | 75 (46/29) | 77 (47/30) | 43 | 67 (35/32) | 65 (33/32) |
| Sex | ||||||
| Male | 20 | 35 (21/14) | 38 (25/13) | 21 | 30 (14/16) | 32 (15/17) |
| Female | 24 | 40 (25/15) | 39 (22/17) | 22 | 37 (21/16) | 33 (18/15) |
| Age, y | 33.2 ± 8.5 | 31.5 ± 8.7 | 35.1 ± 12.3 | 31.2 ± 7.2 | 31.8 ± 7.1 | 34.8 ± 9.6 |
| Disease duration, mo | 42.7 ± 13.6 | 44.8 ± 19.5 | 36.8 ± 15.5 | 41.4 ± 15.3 | ||
| Disease location (CD)a | ||||||
| L1 | 21 (13/8) | 9 (5/4) | ||||
| L2 | 9 (4/5) | 10 (4/6) | ||||
| L3 | 45 (29/16) | 48 (26/22) | ||||
| L4 | 0 | 0 | ||||
| Disease extent (UC)a | ||||||
| E1 | 10 (6/4) | 9 (5/4) | ||||
| E2 | 31 (17/14) | 27 (15/12) | ||||
| E3 | 36 (24/12) | 29 (17/12) | ||||
| Current therapy | ||||||
| Mesalamine | 22 (13/9) | 29 (18/11) | 27 (15/12) | 30 (17/13) | ||
| Biologics | 35 (25/10) | 12 (10/2) | 31 (22/11) | 15 (10/5) | ||
| Azathioprine | 21 (14/7) | 27 (17/10) | 17 (12/5) | 24 (15/9) | ||
| Methotrexate | 8 (5/3) | 0 | 8 (6/2) | 0 | ||
| Glucocorticoids | 19 (19/0) | 31 (28/3) | 16 (11/5) | 27 (23/4) | ||
| CDAI (mean ± SEM) | 228.3 ± 49.4/102.5 ± 27.8 | 211.9 ± 35.7/90.7 ± 20.4 | ||||
| Mayo Score (mean ± SEM) | 6.8±1.9/1.7±0.5 | 5.2 ± 1.4/1.4 ± 0.5 | ||||
Values are n or mean ± SEM, unless otherwise indicated.
A/R, active/remission; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; HC, healthy control; IBD, inflammatory bowel disease; UC, ulcerative colitis.
a
According to the Montreal classification system.